NCT03385655 - Prostate Cancer Biomarker Enrichment and Treatment Selection | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

October 7, 2024

Study Completion Date

December 31, 2025

Conditions

Prostate Cancer

Interventions

DRUG

Adavosertib

250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1

DRUG

Savolitinib

600mg once daily, orally.

DRUG

Darolutamide

600mg twice daily, orally.

DRUG

CFI-400945

Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.

DRUG

Ipatasertib

400mg daily 3 weeks on, 1 week off

DRUG

Durvalumab and Tremelimumab

Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1

DRUG

Carboplatin

AUC 5 IV 60min Day 1 q 21 days

Trial Locations (11)

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 5W9

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

H2X 3E4

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal

H3T 1E2

The Jewish General Hospital, Montreal

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon